11 November 2011



(“Sareum” or the “Company”)

Sareum to Present CHK1 Cancer Research Programme
at the 2011 AACR-NCI-EORTC International Conference

Sareum Holdings plc, the specialist cancer drug discovery business, is pleased to announce that it will present recent results from its joint research collaboration with The Institute of Cancer Research (ICR) and Cancer Research Technology Ltd. (CRT) at the American Association for Cancer Research (AACR) National Cancer Institute (NCI) European Organisation for Research and Treatment of Cancer (EORTC) International Conference, to be held between 12 and 16 November 2011 in San Francisco, CA.

On Sunday November 13, scientists from the ICR and Dr John Reader, Sareum’s CSO, will present two posters* that describe the discovery of CHK1 programme lead compounds and the effectiveness of an advanced lead in cancer models, both as a single agent and in combination with chemotherapy.

The Company is encouraged that some of the significant recent progress made by the joint research collaboration will be presented at a prestigious international cancer conference and believe this will assist in discussions with potential licensing partners.

* Session “Therapeutic agents: Small molecule kinase inhibitors 1”

“Structure-guided evolution of potent and selective oral inhibitors of CHK1 through scaffold morphing.” Abstract # A235

“CCT244747 is a novel, potent and selective inhibitor of CHK1 with oral efficacy both alone and in combination with genotoxic chemotherapeutic agents.” Abstract # A228

Sareum’s CEO, Dr Tim Mitchell, commented: “We are delighted to be presenting these results from this highly successful collaboration at this important cancer conference, at which we expect representatives from most of our potential customer companies to attend.”


Sareum Holdings plc


Tim Mitchell

01223 497 700

Merchant John East Securities Limited (Nomad)

Simon Clements

020 7628 2200

Hybridan LLP (Broker)


Claire Noyce

020 7947 4350


Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in several in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR.  For further information, please visit www.sareum.co.uk